1Cell.Ai Launches OncoIncytes: New AI-Powered Oncology Diagnostics | What is generative ai select the best option | Examples of generative ai tools | Generative ai healthcare companies | Turtles AI

1Cell.Ai, formerly OneCell Diagnostics, introduced OncoIncytes, an AI-powered cancer diagnostic platform that integrates single-cell multi-omics data to improve patient selection and clinical trial efficacy.

Key Points:

• Multi-omics Integration: OncoIncytes combines single-cell ctDNA, CTC, transcriptomics and proteomics.
• Advanced Gene Panel: Utilizes a 1080-gene panel validated with Illumina’s TSO 500 and PGDx.
• ADC Support: Facilitates development of antibody-drug conjugates by identifying specific protein expressions.
• Global Expansion: Following success in India, aims to expand into the US with support from a $16 million Series A financing.

Biotechnology company 1Cell.Ai, formerly known as OneCell Diagnostics, announced the launch of OncoIncytes, an AI-powered cancer diagnostic platform that integrates single-cell, multi-omics data to improve patient selection and clinical trial efficacy. OncoIncytes combines analysis of circulating tumor DNA (ctDNA), single-resolution circulating tumor cells (CTCs), RNA transcriptomics and proteomics, analyzing 150 proteins at the single-cell level. This integration provides detailed information on the molecular profile of tumors, facilitating patient selection for targeted therapies, particularly antibody-drug conjugates (ADCs). The OncoIncytes gene panel comprises 1,080 genes and has been validated against orthogonal NGS panels, such as Illumina’s TSO 500 and FDA-approved PGDx, demonstrating 100% concordance in results. The technology is supported by AI and machine learning models, which improve data interpretation and support clinical decisions. 1Cell.Ai recently raised a $16 million Series A funding round, led by Celesta Capital with participation from Tenacity Ventures, Cedars Sinai, Eragon and Singularity Ventures, to expand its presence in the United States and continue to develop its proprietary cell biopsy technology. The company has already served approximately 10,000 patients in India and collaborates with top-tier academic institutions, including Harvard Medical School, Stanford University and the University of Georgia. The Foster City laboratory is CLIA certified, ensuring high standards of quality and reliability. Test results are made available through the iDiscover app, ensuring rapid and accurate communication with healthcare providers. By rebranding to 1Cell.Ai, the company underscores its commitment to integrating advanced scientific expertise with data science capabilities to offer comprehensive solutions in precision oncology.

With the introduction of OncoIncytes, 1Cell.Ai positions itself as a key player in the evolution of precision oncology, offering advanced diagnostic tools that combine multi-omics analysis and AI to improve the clinical management of cancer patients.